First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC
“The increasing diversity of EGFR mutations has led to a growing number of therapeutic agents targeting various, narrowly defined subsets of EGFR mutation-positive lung cancer. When designing BH-30643, we pursued a different and broader ambition – a highly potent drug capable of inhibiting a wide spectrum of EGFR mutations, while sparing inhibition of wildtype EGFR and HER2, expected to provide a significant survival benefit and a better tolerated therapy for more patients,” said J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill Therapeutics. “With this goal top of mind, we sought to break away from the entrenched thinking present in prior generations of EGFR inhibitor designs. With BH-30643, we seek to address the ongoing unmet medical need for this disease in a safe and effective manner, and we are committed to the rapid advancement of our OMNI-EGFRTM inhibitor in the clinic.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the